Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

  • June 5, 2026

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche helped get the show rolling with a deep dive into their amylin analog petrelintide.

Leave A Comment

Fields (*) Mark are Required